Group 1 - The biopharmaceutical industry is crucial for public welfare and is a key driver for high-quality development in the pharmaceutical sector, with a focus on future industries like quantum technology and biomanufacturing as new economic growth points [1] - Chengdu's Wenjiang District has established a comprehensive biopharmaceutical ecosystem that integrates medical research, healthcare services, and pharmaceutical manufacturing, starting its development in 2008 [1] - The district's government has implemented a "three medicine" integration concept to promote cluster development in the biopharmaceutical industry, breaking down silos between medical research, healthcare, and pharmaceuticals [1] Group 2 - Chengdu Baiyu Pharmaceutical Co., Ltd. is a local biopharmaceutical company that has benefited from government initiatives such as specialized financing and subsidies, which have supported its research and development efforts [2] - Sichuan Baili Tianheng Pharmaceutical Co., Ltd., a leader in innovative cancer therapies, has achieved a significant global collaboration worth $8.4 billion with Bristol-Myers Squibb for its pioneering ADC product [2] - Wenjiang District has attracted key industry players through targeted investment strategies, establishing a distinctive and efficient biopharmaceutical industry chain, including a specialized nuclear medicine industrial park [3] Group 3 - The district has over 650 enterprises in the pharmaceutical and health sectors, forming a complete industrial ecosystem that includes drug research, manufacturing, and medical applications, with significant achievements in innovative drug development [3] - Companies in the region have successfully engaged in international drug licensing transactions, totaling over $24 billion, showcasing their strong research capabilities [3] - Wenjiang District is committed to becoming a leading biopharmaceutical hub in Western China, with plans to enhance support policies for the industry [4]